We currently represent several high quality biotech companies in multi-track licensing and M&A engagements, including:

• A company with a novel drug conjugate that prolongs exposure, enhances safety and efficacy, that has successful completed a Ph Ib trial in lung cancer, available for licensing
• A company with a highly selective, CNS compound, tested in 350 subjects to date, for development as first in class therapy for Huntington's disease (orphan indication), Parkinson's disease and Parkinson's disease dementia, ready for Ph II, available for licensing.
• A company with an IND-ready, direct, reversible, P2Y12 receptor antagonist for acute coronary syndrome and other cardiological indications, available for licensing.
• A company with If channel blocker for cardiovascular disease with potential for best in class for a variety of cardiac indications including heart failure and stable angina, tested in 400 patients with proof of concept in Phase 2 stable angina, available for licensing
• A company with a treatment of complex perianal fistula in patients with Crohn’s disease, with orphan drug status, in a multinational Ph III clinical trial, available for licensing.
• A company with novel monoclonal antibody targeting HGF, ready for Ph II, with excellent safety and indication of activity in gastric cancer, with dominant IP position, available for licensing.
• A company with a potentially best-in-class bronchodilator (long acting muscarinic antagonist) with composition of matter through 2030, for the treatment of COPD and asthma, available for licensing.
• An oral, Ph III, GI orphan drug opportunity, for the treatment of Familial Adenomatous Polyposis, with statistically significant positive Ph III data in a related indication, available for licensing.